The FDA just approved a new, extended-release version of Eli Lilly’s antipsychotic drug Zyprexa. If a classic pharma strategy holds true, the drug may also extend Lilly’s ability to make money from its Zyprexa franchise.
The company is likely to face generic competition on regular-selling Zyprexa in 2011. But a key patent on the extended release version of the drug is valid until 2018, a Lilly spokeswoman told the Health Blog.
Regular Zyprexa is taken every day, and is available as a ..read more